Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Counter-Terrorism Focus, Regulatory Reform Plans Will Impact CDRH

This article was originally published in The Silver Sheet

Executive Summary

NEW FDA COUNTER-TERRORISM INITIATIVES are slated to receive the bulk of any funding increase in FY 2003, leaving little monies for already cash-strapped day-to-day operations. Despite an influx of new hires, the Bush Administration’s goal of a six-fold increase in import product examinations could constrain field efforts to maintain current manufacturer inspection levels. While FDA adjusts its mission focus, consolidation plans within both HHS and FDA are expected to create more streamlined and unified operations. In the midst of these changes, Congress is set to take up a package of medical device reform measures and HHS is reviewing recommendations to ease FDA administrative burdens

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT036067

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel